Corrigendum: MSC therapy ameliorates experimental gouty arthritis hinting an early COX-2 induction

Front Immunol. 2023 Dec 6:14:1345777. doi: 10.3389/fimmu.2023.1345777. eCollection 2023.

¹ Bone and Joint Research Unit, Rheumatology Dept, IIS-Fundación Jiménez Díaz Universidad Autonoma de Madrid (UAM), Madrid, Spain.
² Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), Madrid, Spain.
³ Advanced Therapies Dept, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain.
⁴ New Therapies Laboratory, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain.
⁵ Department of Surgery, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
⁶ Department of Surgery, School of Medicine UAM, Madrid, Spain.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2023.1193179.].

Keywords: COX-2; inflammasome; innate inflammation; macrophage; mesenchymal stem cells (MSCs); polarization; prostaglandin E2.